Harikrishna Nakshatri

List of Publications by Year
in descending order

186	15,627	16437 64	17580 121
papers	citations	h-index	g-index

195	195	195	18931
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell, 1992, 68, 377-395.	13.5	1,218
2	CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Research, 2006, 8, R59.	2.2	839
3	Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor Î±. Journal of Biological Chemistry, 2001, 276, 9817-9824.	1.6	831
4	Constitutive Activation of NF-ÎºB during Progression of Breast Cancer to Hormone-Independent Growth. Molecular and Cellular Biology, 1997, 17, 3629-3639.	1.1	790
5	NF-Îº B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4. Journal of Biological Chemistry, 2003, 278, 21631-21638.	1.6	568
6	NF-ÎºB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene, 2007, 26, 711-724.	2.6	545
7	PROGgeneV2: enhancements on the existing database. BMC Cancer, 2014, 14, 970.	1.1	417
8	Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell, 1992, 70, 1007-1019.	13.5	365
9	Cutting Edge: IL-17F, a Novel Cytokine Selectively Expressed in Activated T Cells and Monocytes, Regulates Angiogenesis and Endothelial Cell Cytokine Production. Journal of Immunology, 2001, 167, 4137-4140.	0.4	320
10	Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Research, 2009, 37, 4850-4861.	6.5	310
11	Paclitaxel sensitivity of breast cancer cells with constitutively active NF-ÎºB is enhanced by IÎºBÎ± super-repressor and parthenolide. Oncogene, 2000, 19, 4159-4169.	2.6	277
12	RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo.. EMBO Journal, 1993, 12, 2349-2360.	3.5	275
13	A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter.. EMBO Journal, 1991, 10, 2223-2230.	3.5	226
14	FOXA1 Expression in Breast Cancerâ€"Correlation with Luminal Subtype A and Survival. Clinical Cancer Research, 2007, 13, 4415-4421.	3.2	220
15	Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10138-10142.	3.3	204
16	Cloning of BRAK, a Novel Divergent CXC Chemokine Preferentially Expressed in Normal versus Malignant Cells. Biochemical and Biophysical Research Communications, 1999, 255, 703-706.	1.0	177
17	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Research and Treatment, 2010, 123, 97-108.	1.1	165
18	Nuclear Factor-ÎºB Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate. Clinical Cancer Research, 2004, 10, 5501-5507.	3.2	157

#	Article	IF	Citations
19	SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype. BMC Cancer, 2010, 10, 411.	1.1	155
20	Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature, 1988, 335, 832-835.	13.7	146
21	The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Molecular Cancer Therapeutics, 2005, 4, 1004-1012.	1.9	145
22	Identity Profiling of Cell Surface Markers by Multiplex Gold Nanorod Probes. Nano Letters, 2007, 7, 2300-2306.	4.5	144
23	Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene, 2004, 23, 7330-7344.	2.6	141
24	PROGgene: gene expression based survival analysis web application for multiple cancers. Journal of Clinical Bioinformatics, 2013, 3, 22.	1.2	140
25	The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo- and heterodimers.. Journal of Biological Chemistry, 1994, 269, 890-902.	1.6	139
26	Breast-cancer stem cellsâ€"beyond semantics. Lancet Oncology, The, 2012, 13, e43-e48.	5.1	137
27	Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnology, 2012, 3, 47-54.	1.9	132
28	The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4, and ARP-1 homo- and heterodimers. Journal of Biological Chemistry, 1994, 269, 890-902.	1.6	121
29	Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery, 2009, 146, 258-263.	1.0	118
30	Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene, 2011, 30, 1290-1301.	2.6	115
31	Identification of signal transduction pathways involved in constitutive NF-Î²B activation in breast cancer cells. Oncogene, 2002, 21, 2066-2078.	2.6	114
32	Epithelial-to-Mesenchymal Transition and Ovarian Tumor Progression Induced by Tissue Transglutaminase. Cancer Research, 2009, 69, 9192-9201.	0.4	114
33	Repression of transforming-growth-factor-Î²-mediated transcription by nuclear factor ÎºB. Biochemical Journal, 2000, 348, 591-596.	1.7	111
34	FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Research and Treatment, 2012, 131, 881-890.	1.1	111
35	Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs, 2004, 22, 299-305.	1.2	109
36	Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-ÎºB pathway in pancreatic carcinoma cells. Molecular Cancer Therapeutics, 2005, 4, 587-594.	1.9	108

#	Article	IF	Citations
37	Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase. Cancer Research, 2007, 67, 7194-7202.	0.4	108
38	Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene, 2007, 26, 3329-3337.	2.6	105
39	Repression of GADD153/CHOP by NF-Î¹B: a possible cellular defense against endoplasmic reticulum stress-induced cell death. Oncogene, 2001, 20, 2178-2185.	2.6	104
40	ANTXR1, a Stem Cell-Enriched Functional Biomarker, Connects Collagen Signaling to Cancer Stem-like Cells and Metastasis in Breast Cancer. Cancer Research, 2013, 73, 5821-5833.	0.4	104
41	Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On. Current Stem Cell Research and Therapy, 2009, 4, 50-60.	0.6	102
42	CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 3967-3971.	3.3	101
43	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. Journal of Clinical Pathology, 2007, 61, 327-332.	1.0	101
44	Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer. Clinical Cancer Research, 2006, 12, 1883-1896.	3.2	100
45	Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. Journal of Pathology, 2014, 232, 369-381.	2.1	98
46	Flower isoforms promote competitive growth inÂcancer. Nature, 2019, 572, 260-264.	13.7	96
47	An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Clinical Cancer Research, 2018, 24, 3163-3175.	3.2	93
48	Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements. Nucleic Acids Research, 1998, 26, 2491-2499.	6.5	92
49	Subunit Association and DNA Binding Activity of the Heterotrimeric Transcription Factor NF-Y Is Regulated by Cellular Redox. Journal of Biological Chemistry, 1996, 271, 28784-28791.	1.6	88
50	Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis, 2008, 29, 1893-1900.	1.3	88
51	AKT Alters Genome-Wide Estrogen Receptor Î± Binding and Impacts Estrogen Signaling in Breast Cancer. Molecular and Cellular Biology, 2008, 28, 7487-7503.	1.1	87
52	Mutational landscape of RNA-binding proteins in human cancers. RNA Biology, 2018, 15, 115-129.	1.5	87
53	Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Research, 2011, 13, R86.	2.2	83
54	RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO Journal, 1993, 12, 2349-60.	3.5	82

#	Article	IF	Citations
55	HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ERÎ± and Inducing IL-6 Expression. Cancer Research, 2013, 73, 5449-5458.	0.4	80
56	Inhibiting Proteasomal Proteolysis Sustains Estrogen Receptor-Î± Activation. Molecular Endocrinology, 2004, 18, 2603-2615.	3.7	78
57	NF-ÂB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1Â. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 6971-6976.	3.3	78
58	Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. Journal of Clinical Pathology, 2009, 62, 6-12.	1.0	74
59	Interleukin-1Î± Promotes Tumor Growth and Cachexia in MCF-7 Xenograft Model of Breast Cancer. American Journal of Pathology, 2003, 163, 2531-2541.	1.9	72
60	A water soluble parthenolide analog suppresses in vivo tumor growth of two tobaccoâ€associated cancers, lung and bladder cancer, by targeting NFâ€Î²B and generating reactive oxygen species. International Journal of Cancer, 2011, 128, 2481-2494.	2.3	72
61	HOXB7 Is an ERÎ± Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer Discovery, 2015, 5, 944-959.	7.7	72
62	Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis, 2008, 29, 25-34.	1.3	71
63	A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter. EMBO Journal, 1991, 10, 2223-30.	3.5	68
64	NF-Î²B inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Letters, 2009, 278, 145-155.	3.2	67
65	Cancer Cell-Derived Interleukin 1Î± Contributes to Autocrine and Paracrine Induction of Pro-metastatic Genes in Breast Cancer. Biochemical and Biophysical Research Communications, 2000, 275, 60-62.	1.0	64
66	NF-Î²B and breast cancer. Current Problems in Cancer, 2002, 26, 282-309.	1.0	62
67	The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1Î±/CXCL12. Carcinogenesis, 2005, 26, 1706-1715.	1.3	61
68	FOXA1 as a therapeutic target for breast cancer. Expert Opinion on Therapeutic Targets, 2007, 11, 507-514.	1.5	61
69	FOXA1 in breast cancer. Expert Reviews in Molecular Medicine, 2009, 11, e8.	1.6	60
70	A waterâ€soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFÎ²B and generating reactive oxygen species. Prostate, 2010, 70, 1074-1086.	1.2	60
71	PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data. Journal of Clinical Bioinformatics, 2012, 2, 23.	1.2	58
72	High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology, 2011, 58, 766-772.	1.6	57

#	Article	IF	Citations
73	Interaction of Oct-1 with TFIIB. Journal of Biological Chemistry, 1995, 270, 19613-19623.	1.6	56
74	Negative Regulation of Transactivation Function but Not DNA Binding of NF-Î²B and AP-1 by IÎºBÎ²1 in Breast Cancer Cells. Journal of Biological Chemistry, 1999, 274, 18827-18835.	1.6	56
75	The Platelet-derived Growth Factor Receptor Î± Is Destabilized by Geldanamycins in Cancer Cells. Journal of Biological Chemistry, 2007, 282, 445-453.	1.6	56
76	Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity. Scientific Reports, 2013, 3, 2530.	1.6	53
77	Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells. Oncotarget, 2015, 6, 12682-12696.	0.8	52
78	NF-Î²B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death and Disease, 2015, 6, e1608-e1608.	2.7	48
79	A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells. Cell Reports Medicine, 2021, 2, 100219.	3.3	48
80	Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase. Blood, 1998, 92, 2450-2460.	0.6	47
81	Retinoic Acid Signal Transduction Pathways. Annals of the New York Academy of Sciences, 1993, 684, 19-34.	1.8	45
82	Stage and tissue-specific expression of the alcohol dehydrogenase 1 (Adh-1) gene during mouse development. Developmental Dynamics, 1994, 199, 199-213.	0.8	45
83	Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization. Scientific Reports, 2015, 5, 13526.	1.6	45
84	Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 2006, 66, 1498-1511.	1.2	44
85	Cancer Affects microRNA Expression, Release, and Function in Cardiac and Skeletal Muscle. Cancer Research, 2014, 74, 4270-4281.	0.4	44
86	Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Modern Pathology, 2010, 23, 270-275.	2.9	43
87	Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells. Cancer Research, 2018, 78, 3865-3876.	0.4	43
88	Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade. Cancer Research, 2018, 78, 5107-5123.	0.4	42
89	The Platelet-activating Factor Receptor Protects Epidermal Cells from Tumor Necrosis Factor (TNF) Î± and TNF-related Apoptosis-inducing Ligand-induced Apoptosis through an NF-Î²B-dependent Process. Journal of Biological Chemistry, 2001, 276, 45548-45554.	1.6	41
90	The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. International Journal of Oncology, 2014, 44, 2009-2015.	1.4	41

#	Article	IF	Citations
91	The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis, 2005, 26, 900-907.	1.3	40
92	Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers. American Journal of Pathology, 2010, 176, 2139-2149.	1.9	40
93	Inflammation-associated microRNA changes in circulating exosomes of heart failure patients. BMC Research Notes, 2017, 10, 751.	0.6	40
94	Skeletal loading regulates breast cancer-associated osteolysis in a loading intensity-dependent fashion. Bone Research, 2020, 8, 9.	5.4	40
95	Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Molecular Cancer Therapeutics, 2007, 6, 1736-1744.	1.9	39
96	Repression of transforming-growth-factor-Î²-mediated transcription by nuclear factor ÎºB. Biochemical Journal, 2000, 348, 591.	1.7	37
97	Transformation of interleukin-3â€“dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor ÎºBâ€“mediated antiapoptosis involving c-IAP2. Blood, 2001, 98, 2508-2517.	0.6	37
98	Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide. Clinical Cancer Research, 2008, 14, 1814-1822.	3.2	37
99	The Orphan Receptor COUP-TFII Regulates G2/M Progression of Breast Cancer Cells by Modulating the Expression/Activity of p21WAF1/CIP1, Cyclin D1, and cdk2. Biochemical and Biophysical Research Communications, 2000, 270, 1144-1153.	1.0	35
100	Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis. Scientific Reports, 2017, 7, 45686.	1.6	35
101	Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. Cancers, 2021, 13, 369.	1.7	35
102	Ubiquitous and cell-type-specific protein interactions with human papillomavirus type 16 and type 18 enhancers. Virology, 1990, 178, 92-103.	1.1	34
103	MMB triazole analogs are potent NF-ÎºB inhibitors and anti-cancer agents against both hematological and solid tumor cells. European Journal of Medicinal Chemistry, 2018, 157, 562-581.	2.6	34
104	Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein. Blood, 2001, 97, 2168-2170.	0.6	33
105	Retinoid receptors and binding proteins. Journal of Cell Science, 1992, 1992, 69-76.	1.2	32
106	Binding and activation of the human aldehyde dehydrogenase 2 promoter by hepatocyte nuclear factor 4. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1399, 181-186.	2.4	32
107	Parthenolide Sensitizes Cells to X-Ray-Induced Cell Killing through Inhibition of NF-ÎºB and Split-Dose Repair. Radiation Research, 2007, 168, 689-697.	0.7	32
108	Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis. Journal of Medicinal Chemistry, 2011, 54, 7193-7205.	2.9	32

#	Article	IF	Citations
109	Isolation of retinoic acid-repressed genes from P19 embryonal carcinoma cells. Gene, 1996, 174, 79-84.	1.0	31
110	MOZ and MOZ-CBP cooperate with NF-Î¹B to activate transcription from NF-Î¹Bâ€“dependent promoters. Experimental Hematology, 2007, 35, 1782-1792.	0.2	31
111	TFAP2C expression in breast cancer: correlation with overall survival beyond 10Âyears of initial diagnosis. Breast Cancer Research and Treatment, 2015, 152, 519-531.	1.1	30
112	Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. British Journal of Cancer, 2004, 90, 853-859.	2.9	28
113	Microfluidic channel for characterizing normal and breast cancer cells. Journal of Micromechanics and Microengineering, 2017, 27, 035017.	1.5	28
114	Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. Cancer Research, 2016, 76, 3989-4001.	0.4	27
115	In vivoÂmodeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genetics, 2020, 16, e1008808.	1.5	27
116	Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity. Science Advances, 2022, 8, eabh3375.	4.7	27
117	Cell competition and tumor heterogeneity. Seminars in Cancer Biology, 2020, 63, 1-10.	4.3	26
118	Interplay between estrogen receptor and AKT in Estradiol-induced alternative splicing. BMC Medical Genomics, 2013, 6, 21.	0.7	25
119	Overexpression of Lrp5 enhanced the anti-breast cancer effects of osteocytes in bone. Bone Research, 2021, 9, 32.	5.4	25
120	2-Methoxyestradiol Inhibits the Anaphase-Promoting Complex and Protein Translation in Human Breast Cancer Cells. Cancer Research, 2007, 67, 702-708.	0.4	24
121	Loss of ERÎ± and FOXA1 expression in a progression model of luminal type breast cancer: Insights from PyMT transgenic mouse model. Oncology Reports, 2010, 24, 1233-9.	1.2	24
122	Prognosis of Hormone-Dependent Breast Cancers: Implications of the Presence of Dysfunctional Transcriptional Networks Activated by Insulin via the Immune Transcription Factor T-bet. Cancer Research, 2010, 70, 685-696.	0.4	23
123	Reduction in Migratory Phenotype in a Metastasized Breast Cancer Cell Line via Downregulation of S100A4 and GRM3. Scientific Reports, 2017, 7, 3459.	1.6	23
124	Attraction and Compaction of Migratory Breast Cancer Cells by Bone Matrix Proteins through Tumor-Osteocyte Interactions. Scientific Reports, 2018, 8, 5420.	1.6	23
125	Genetic Ancestryâ€“dependent Differences in Breast Cancerâ€“induced Field Defects in the Tumor-adjacent Normal Breast. Clinical Cancer Research, 2019, 25, 2848-2859.	3.2	23
126	Radiation resistance in breast cancer: are CD44+/CD24-/proteosomelow/PKH26+cells to blame?. Breast Cancer Research, 2010, 12, 105.	2.2	22

#	Article	IF	Citations
127	A system for detecting high impact-low frequency mutations in primary tumors and metastases. Oncogene, 2018, 37, 185-196.	2.6	21
128	Interferon-Î³ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer. Npj Precision Oncology, 2019, 3, 32.	2.3	21
129	Negative regulation of MHC class II gene expression by CXCR4. Experimental Hematology, 2006, 34, 1085-1092.	0.2	19
130	Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2747-2758.	1.9	19
131	Functional role of BK virus tumor antigens in transformation. Journal of Virology, 1988, 62, 4613-4621.	1.5	19
132	Aged Breast Extracellular Matrix Drives Mammary Epithelial Cells to an Invasive and Cancerâ€Like Phenotype. Advanced Science, 2021, 8, e2100128.	5.6	19
133	Activity and enhancer binding factors for jc virus regulatory elements in differentiating embryonal carcinoma cells. Virology, 1990, 177, 784-789.	1.1	18
134	Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. Nature Communications, 2019, 10, 2860.	5.8	18
135	Biomarkers for breast cancer stem cells: the challenges ahead. Biomarkers in Medicine, 2011, 5, 661-671.	0.6	17
136	Individualized Breast Cancer Characterization through Single-Cell Analysis of Tumor and Adjacent Normal Cells. Cancer Research, 2017, 77, 2759-2769.	0.4	16
137	Dual TGFÎ²/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast. Molecular Cancer Research, 2019, 17, 1556-1570.	1.5	16
138	ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Cancer Biology and Therapy, 2010, 10, 600-614.	1.5	15
139	Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis. Breast Cancer Research, 2018, 20, 35.	2.2	14
140	Aberrant epigenetic and transcriptional events associated with breast cancer risk. Clinical Epigenetics, 2022, 14, 21.	1.8	14
141	Intrinsic subtypeâ€associated changes in the plasma proteome in breast cancer. Proteomics - Clinical Applications, 2009, 3, 1305-1313.	0.8	13
142	Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model. Oncotarget, 2018, 9, 9364-9378.	0.8	13
143	The first 124 nucleotides of the E7 coding sequences of HPV16 can render the HPV11 genome transformation competent. Virology, 1992, 186, 348-351.	1.1	12
144	TNFÎ± resistance in MCF-7 breast cancer cells is associated with altered subcellular localization of p21CIP1 and p27KIP1. Cell Death and Differentiation, 2005, 12, 98-100.	5.0	12

#	Article	IF	Citations
145	Striatin-3Î³ inhibits estrogen receptor activity by recruiting a protein phosphatase. Journal of Molecular Endocrinology, 2008, 40, 199-210.	1.1	12
146	A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples. Journal of Translational Medicine, 2011, 9, 80.	1.8	12
147	Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression. Oncogene, 2021, 40, 1332-1346.	2.6	12
148	Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling. International Journal of Oncology, 2018, 53, 1001-1012.	1.4	11
149	Breast Cancer Cell Detection and Characterization from Breast Milkâ€“Derived Cells. Cancer Research, 2020, 80, 4828-4839.	0.4	11
150	Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7â€“APEHâ€“Proteasome Axis in High-grade Serous Ovarian Carcinoma. Molecular Cancer Research, 2021, 19, 1168-1181.	1.5	11
151	Amplified in breast cancer 1 expression in breast cancer. Histopathology, 2008, 53, 634-641.	1.6	10
152	Essential Components of Cancer Education. Cancer Research, 2015, 75, 5202-5205.	0.4	10
153	Activity and enhancer binding factors for BK virus regulatory elements in differentiating embryonal carcinoma cells. Virology, 1991, 183, 374-380.	1.1	9
154	Differential Effect of Nonidet P40 on DNA Binding of Transcription Factors. Analytical Biochemistry, 1997, 249, 103-104.	1.1	9
155	Distinct Effects of Adipose-Derived Stem Cells and Adipocytes on Normal and Cancer Cell Hierarchy. Molecular Cancer Research, 2016, 14, 660-671.	1.5	9
156	Systemic Actions of Breast Cancer Facilitate Functional Limitations. Cancers, 2020, 12, 194.	1.7	9
157	FAM83A is a potential biomarker for breast cancer initiation. Biomarker Research, 2022, 10, 8.	2.8	9
158	Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer. Journal of Surgical Research, 2007, 143, 169-176.	0.8	7
159	Building a virtual summer research experience in cancer for high school and early undergraduate students: lessons from the COVID-19 pandemic. BMC Medical Education, 2021, 21, 422.	1.0	7
160	Role of <scp>AKT</scp> isotypes in breast cancer. Journal of Pathology, 2013, 229, e1.	2.1	6
161	Bidirectional Regulatory Cross-Talk between Cell Context and Genomic Aberrations Shapes Breast Tumorigenesis. Molecular Cancer Research, 2021, 19, 1802-1817.	1.5	6
162	Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase. Blood, 1998, 92, 2450-2460.	0.6	6

#	Article	IF	Citations
163	Acquisition, processing, and single-cell analysis of normal human breast tissues from a biobank. STAR Protocols, 2022, 3, 101047.	0.5	6
164	RareVar: A Framework for Detecting Low-Frequency Single-Nucleotide Variants. Journal of Computational Biology, 2017, 24, 637-646.	0.8	5
165	A spectrum graph-based protein sequence filtering algorithm for proteoform identification by top-down mass spectrometry. , 2017, 2017, 222-229.		5
166	regSNPs-ASB: A Computational Framework for Identifying Allele-Specific Transcription Factor Binding From ATAC-seq Data. Frontiers in Bioengineering and Biotechnology, 2020, 8, 886.	2.0	5
167	Agingâ€associated skeletal muscle defects in HER2/Neu transgenic mammary tumour model. JCSM Rapid Communications, 2021, 4, 24-39.	0.6	5
168	Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations. Molecular Therapy - Nucleic Acids, 2022, 28, 231-248.	2.3	5
169	Statistical modeling for sensitive detection of low-frequency single nucleotide variants. BMC Genomics, 2016, 17, 514.	1.2	4
170	A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment. PLoS ONE, 2021, 16, e0225869.	1.1	4
171	Mechanical tibial loading remotely suppresses brain tumors by dopamine-mediated downregulation of CCN4. Bone Research, 2021, 9, 26.	5.4	4
172	Hormonally Regulated Myogenic miR-486 Influences Sex-specific Differences in Cancer-induced Skeletal Muscle Defects. Endocrinology, 2021, 162, .	1.4	4
173	Antitumor properties of novel sesquiterpene lactone analogs as NFÎºB inhibitors that bind to the IKKÎ² ubiquitin-like domain (ULD). European Journal of Medicinal Chemistry, 2021, 224, 113675.	2.6	4
174	Differential Whole-Cell Extract Preparation and Electrophoretic Mobility Shift Assay to Evaluate the Effect of Tyrosine Phosphatases on DNA Binding Activity of Transcription Factors. Analytical Biochemistry, 1996, 236, 178-181.	1.1	3
175	Metabolic Links to Socioeconomic Stresses Uniquely Affecting Ancestry in Normal Breast Tissue at Risk for Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	3
176	Breast Heterogeneity: Obstacles to Developing Universal Biomarkers of Breast Cancer Initiation and Progression. Journal of the American College of Surgeons, 2020, 231, 85-96.	0.2	2
177	FOXA1 (forkhead box A1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	1
178	The Sesquiterpene Lactone Parthenolide Induces Apoptosis and Overcomes the Protective Effect of the Bone Marrow Microenvironment in Human Multiple Myeloma Cells.. Blood, 2006, 108, 5058-5058.	0.6	1
179	Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer. Journal of Clinical Oncology, 2006, 24, 539-539.	0.8	1
180	Journal Watch: Our expert highlights the most important research articles across a spectrum of topics relevant to the field of breast cancer management.. Breast Cancer Management, 2012, 1, 117-118.	0.2	0

#	Article	IF	Citations
181	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of breast cancer management. Breast Cancer Management, 2013, 2, 189-191.	0.2	0
182	Journal Watch: Our expert highlights the most important research articles across the spectrum of topics relevant to the field of breast cancer management. Breast Cancer Management, 2013, 2, 97-99.	0.2	0
183	Correlation of FOXA1 expression with Oncotype Dx recurrence scores. Journal of Clinical Oncology, 2009, 27, 11058-11058.	0.8	0
184	MicroRNA and Cancer Drug Resistance. , 2014, , 305-326.		0
185	Will PI3K-targeted therapies for cancer become a reality?. Translational Cancer Research, 2017, 6, S371-S375.	0.4	0
186	Abstract P3-14-13: Metabolic links to socioeconomic stresses uniquely affecting race in normal breast tissue at risk for breast cancer. Cancer Research, 2022, 82, P3-14-13-P3-14-13.	0.4	0